Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc., Docket No. 24-889

This ruling protects generic drug competition while still holding companies accountable if they cross the line into deliberately promoting patented uses. For patients and consumers, it means generic drugs will remain a competitive force in the market. For brand-name companies, it means they need clear evidence of intentional wrongdoing, not just circumstantial suggestions, to win these lawsuits.music for the podcast provided by ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Dimitry Taras